Fourth Dose of COVID-19 Vaccines Among the Immunocompromised Population (ICPs)
The Secretary of Health (SOH) approved the HTAC recommendation on April 21 to finance a fourth dose of COVID-19 Vaccines AstraZeneca, CoronaVac, Moderna, Pfizer-BioNTech, and Sinopharm among the immunocompromised population (ICPs) ages 18 years old and above given at least 3 months after the third dose, and include these vaccines in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP). While continue reading : Fourth Dose of COVID-19 Vaccines Among the Immunocompromised Population (ICPs)
Preliminary Recommendation for the Inclusion of Potassium Citrate 1620 mg (15 mEq) Tablet in the PNF
Document link: HTAC Preliminary Recommendation of Potassium Citrate 15mEq Tablet (Proponents may submit appeals to hta@doh.gov.ph until 27 April 2022.) Document Preview:
Use of Self-Administered Antigen Testing for COVID-19
Date of publication: 07 April 2022 Signed by the Secretary of Health: 28 June 2022 Objectives: HTA Council Recommendation: Evidence Summary: